Discovery of dual S-RBD/NRP1-targeting peptides: structure-based virtual screening, synthesis, biological evaluation, and molecular dynamics simulation studies

References

• Michailidis E, Kirby KA, Hachiya A, Yoo W, Hong SP, Kim S-O, Folk WR, Sarafianos SG. Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol. 2012;44(7):1060–1071.
   PubMed Web of Science ®Google Scholar
• Namasivayam V, Vanangamudi M, Kramer VG, Kurup S, Zhan P, Liu X, Kongsted J, Byrareddy SN. The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic. J Med Chem. 2019;62(10):4851–4883.
   PubMed Web of Science ®Google Scholar
• Menéndez-Arias L, Delgado R. Update and latest advances in antiretroviral therapy. Trends Pharmacol Sci. 2022;43(1):16–29.
   PubMed Web of Science ®Google Scholar
• Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem. 2014;57(19):7874–7887.
   PubMed Web of Science ®Google Scholar
• Wang Z, Vince R. Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: introducing a diketoacid functionality into delavirdine. Bioorg Med Chem. 2008;16(7):3587–3595.
   PubMed Web of Science ®Google Scholar
• Shang E, Yuan Y, Chen X, Liu Y, Pei J, Lai L. De novo design of multitarget ligands with an iterative fragment-growing strategy. J Chem Inf Model. 2014;54(4):1235–1241.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang X, Wang H, Pu J, Li Q, Li J, Liu Y, Lu L, Jiang S. A "two-birds-one-stone" approach toward the design of bifunctional human immunodeficiency virus type 1 entry inhibitors targeting the CCR5 coreceptor and gp41 N-terminal heptad repeat region. J Med Chem. 2021;64(15):11460–11471.
   PubMed Web of Science ®Google Scholar
• Zhou J, Jiang X, He S, Jiang H, Feng F, Liu W, Qu W, Sun H. Rational design of multitarget-directed ligands: strategies and emerging paradigms. J Med Chem. 2019;62(20):8881–8914.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020;55(6):105948.
   PubMed Web of Science ®Google Scholar
• Li H, Cheng C, Li S, Wu Y, Liu Z, Liu M, Chen J, Zhong Q, Zhang X, Liu S, et al. Discovery and structural optimization of 3-O-β-chacotriosyl oleanane-type triterpenoids as potent entry inhibitors of SARS-CoV-2 virus infections. Eur J Med Chem. 2021;215:113242.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
   PubMed Web of Science ®Google Scholar
• Kielian M. Enhancing host cell infection by SARS-CoV-2. Science. 2020;370(6518):765–766.
   PubMed Web of Science ®Google Scholar
• Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–220.
   PubMed Web of Science ®Google Scholar
• Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020;30(4):343–355.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Zhu Z-L, Qiu X-D, Wu S, Liu Y-T, Zhao T, Sun Z-H, Li Z-R, Shan G-Z. Blocking effect of demethylzeylasteral on the Interaction between human ACE2 protein and SARS-CoV-2 RBD protein discovered using SPR technology. Molecules. 2020;26(1):57.
   PubMed Web of Science ®Google Scholar
• Yu S, Zhu Y, Xu J, Yao G, Zhang P, Wang M, Zhao Y, Lin G, Chen H, Chen L, et al. Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2. Phytomedicine. 2021;85:153364.
   PubMed Web of Science ®Google Scholar
• Ohashi H, Watashi K, Saso W, Shionoya K, Iwanami S, Hirokawa T, Shirai T, Kanaya S, Ito Y, Kim KS, et al. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience. 2021;24(4):102367.
   PubMed Web of Science ®Google Scholar
• Qiao B, Olvera de la Cruz M. Enhanced binding of SARS-CoV-2 spike protein to receptor by distal polybasic cleavage sites. ACS Nano. 2020;14(8):10616–10623.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang S, Li D, Chen P, Han S, Zhao G, Chen Y, Zhao J, Xiong J, Qiu J, et al. Human cathelicidin inhibits SARS-CoV-2 infection: killing two birds with one stone. ACS Infect Dis. 2021;7(6):1545–1554.
   PubMed Web of Science ®Google Scholar
• Chapoval SP, Keegan AD. Perspectives and potential approaches for targeting neuropilin 1 in SARS-CoV-2 infection. Mol Med. 2021;27(1):162.
   PubMed Web of Science ®Google Scholar
• Saiz ML, DeDiego ML, López-García D, Corte-Iglesias V, Baragaño Raneros A, Astola I, Asensi V, López-Larrea C, Suarez-Alvarez B. Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity. Clin Epigenetics. 2021;13(1):187.
   PubMed Web of Science ®Google Scholar
• Tillo M, Erskine L, Cariboni A, Fantin A, Joyce A, Denti L, Ruhrberg C. VEGF189 binds NRP1 and is sufficient for VEGF/NRP1-dependent neuronal patterning in the developing brain. Development. 2015;142(2):314–319.
   PubMed Web of Science ®Google Scholar
• Gioelli N, Neilson LJ, Wei N, Villari G, Chen W, Kuhle B, Ehling M, Maione F, Willox S, Brundu S, et al. Neuropilin 1 and its inhibitory ligand mini-tryptophanyl-tRNA synthetase inversely regulate VE-cadherin turnover and vascular permeability. Nat Commun. 2022;13(1):4188.
   PubMed Web of Science ®Google Scholar
• Mehta V, Fields L, Evans IM, Yamaji M, Pellet-Many C, Jones T, Mahmoud M, Zachary I. VEGF (Vascular Endothelial Growth Factor) induces NRP1 (Neuropilin-1) cleavage via ADAMs (a Disintegrin and Metalloproteinase) 9 and 10 to generate novel carboxy-terminal NRP1 fragments that regulate angiogenic signaling. Arterioscler Thromb Vasc Biol. 2018;38(8):1845–1858.
   PubMed Web of Science ®Google Scholar
• Jarvis A, Allerston CK, Jia H, Herzog B, Garza-Garcia A, Winfield N, Ellard K, Aqil R, Lynch R, Chapman C, et al. Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem. 2010;53(5):2215–2226.
   PubMed Web of Science ®Google Scholar
• Powell J, Mota F, Steadman D, Soudy C, Miyauchi JT, Crosby S, Jarvis A, Reisinger T, Winfield N, Evans G, et al. Small molecule Neuropilin-1 antagonists combine antiangiogenic and antitumor activity with immune modulation through reduction of Transforming Growth Factor Beta (TGFβ) production in regulatory T-cells. J Med Chem. 2018;61(9):4135–4154.
   PubMed Web of Science ®Google Scholar
• Daly JL, Simonetti B, Klein K, Chen K-E, Williamson MK, Antón-Plágaro C, Shoemark DK, Simón-Gracia L, Bauer M, Hollandi R, et al. C et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020;370(6518):861–865.
   PubMed Web of Science ®Google Scholar
• Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, van der Meer F, Kallio K, Kaya T, Anastasina M, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020;370(6518):856–860.
   PubMed Web of Science ®Google Scholar
• Davies J, Randeva HS, Chatha K, Hall M, Spandidos DA, Karteris E, Kyrou I. Neuropilin‑1 as a new potential SARS‑CoV‑2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID‑19. Mol Med Rep. 2020;22(5):4221–4226.
   PubMed Web of Science ®Google Scholar
• Wójcik P, Berlicki Ł. Ł. Peptide-based inhibitors of protein − protein interactions. Bioorg Med Chem Lett. 2016;26(3):707–713.
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, Jain S, Papaioannou I, Laing P. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int J Pharm. 2005;300(1-2):125–130.
   PubMed Web of Science ®Google Scholar
• Han Y, Gao Z, Chen L, Kang L, Huang W, Jin M, Wang Q, Bae YH. Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins. Acta Pharm Sin B. 2019;9(5):902–922.
   PubMed Web of Science ®Google Scholar
• Xu Z, Zou Y, Gao X, Niu M-M, Li J, Xue L, Jiang S. Dual-targeting cyclic peptides of receptor-binding domain (RBD) and main protease (Mpro) as potential drug leads for the treatment of SARS-CoV-2 infection. Front Pharmacol. 2022;13:1041331.
   PubMedGoogle Scholar
• Yang D-S, Yang Y-H, Zhou Y, Yu L-L, Wang R-H, Di B, Niu M-M. A redox-triggered bispecific supramolecular nano-medicine based on peptide self-assembly for high-efficacy and low-toxic cancer therapy. Adv Funct Mater. 2020;30(4):1904969.
   Web of Science ®Google Scholar
• Meyer C, Schepmann D, Yanagisawa S, Yamaguchi J, Dal Col V, Laurini E, Itami K, Pricl S, Wünsch B. Pd-catalyzed direct C-H bond functionalization of spirocyclic σ1 ligands: generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the σ1 receptor. J Med Chem. 2012;55(18):8047–8065.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zou Y, Yang M, Mei S, Liu X, Han H, Zhang C-D, Niu M-M. Highly potent, selective, biostable, and cell-permeable cyclic d-peptide for dual-targeting therapy of lung cancer. J Am Chem Soc. 2022;144(16):7117–7128.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263.
   PubMed Web of Science ®Google Scholar
• Zhou YJ, Tang S, Chen TT, Niu M-M. Structure-Based pharmacophore modeling, virtual screening, molecular docking and biological evaluation for identification of potential poly (ADP-Ribose) polymerase-1 (PARP-1) inhibitors. Molecules. 2019;24(23):4258.
   PubMed Web of Science ®Google Scholar
• Maas MN, Hintzen JCJ, Löffler PMG, Mecinović J. Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides. Chem Commun. 2021;57(26):3283–3286.
   PubMed Web of Science ®Google Scholar
• Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, Zhang L, Nie L, Qin H, Wang M, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):680–686.
   PubMed Web of Science ®Google Scholar
• Yu J, Li Z, He X, Gebre MS, Bondzie EA, Wan H, Jacob-Dolan C, Martinez DR, Nkolola JP, Baric RS, et al. Deletion of the SARS-CoV-2 spike cytoplasmic tail increases infectivity in pseudovirus neutralization assays. J Virol. 2021;95(11):e00044-21.
   PubMed Web of Science ®Google Scholar
• Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, Dai J, Sun Q, Zhao F, Qu J, et al. A et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020;80(4):388–393.
   PubMed Web of Science ®Google Scholar
• Mao R, Qiu Y, He J-S, Tan J-Y, Li X-H, Liang J, Shen J, Zhu L-R, Chen Y, Iacucci M, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(7):667–678.
   PubMed Web of Science ®Google Scholar
• Akhmerov A, Marbán E. COVID-19 and the Heart. Circ Res. 2020;126(10):1443–1455.
   PubMed Web of Science ®Google Scholar